Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.36 |
| ▸ | M6PR | P20645 | 2/20 | 0.35 |
| ▸ | FGF2 | P09038 | 1/20 | 0.34 |
| ▸ | IDUA | P35475 | 1/20 | 0.33 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.33 |
| ▸ | HPSE | Q9Y251 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18412631 | 0.89 | M6PR (0.38) | AKT1SUCNR1M6PRFGF2IDUA | |
| SCHEMBL8267592 | 0.89 | FGF2 (0.37) | AKT1SUCNR1M6PRFGF2IDUA | |
| SCHEMBL18372818 | 0.89 | FGF2 (0.37) | AKT1SUCNR1M6PRFGF2IDUA | |
| SCHEMBL8267517 | 0.89 | M6PR (0.38) | AKT1SUCNR1M6PRFGF2IDUA | |
| SCHEMBL13814803 | 0.89 | FGF2 (0.37) | AKT1SUCNR1M6PRFGF2IDUA | |
| SCHEMBL21065667 | 0.89 | M6PR (0.38) | AKT1SUCNR1M6PRFGF2IDUA | |
| SCHEMBL24694355 | 0.82 | FGF2 (0.43) | AKT1SUCNR1M6PRFGF2IDUA | |
| SCHEMBL6123480 | 0.81 | M6PR (0.36) | SUCNR1M6PRFGF2LGALS8 | |
| SCHEMBL12703785 | 0.81 | M6PR (0.36) | SUCNR1M6PRFGF2LGALS8 | |
| SCHEMBL21540433 | 0.81 | M6PR (0.41) | AKT1SUCNR1M6PRFGF2LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120282331-A1 | MAMMALIAN METABOLITES OF STEROIDS | TOKAI PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120282331-A1 | MAMMALIAN METABOLITES OF STEROIDS | NR5A1, CYP11B2, CYP11B1 | AKT1 2232/4885SUCNR1 105/4885M6PR 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.